Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial -

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
Information type: Randomised controlled trials
Source: The Lancet Neurology
Specialities: Neurological disorders
Summary
In this RCT (n=258) ozanimod 0.5mg and 1mg reduced the mean cumulative number of gadolinium-enhancing lesions at week 24 (OR 0.16 [95%CI=0.08-0.30] and OR 0.11 [0.06-0.21] respectively). No serious infectious or cardiac adverse events were reported.
UKMi comment
Ozanimod is a selective sphingosine 1-phosphate 1 receptor modulator (S1P1R) currently under investigation. A related editorial discusses the potential implications of the research so far. It notes that although the safety profile of ozanimod treatment appears promising, at this stage of development this was also the case for fingolimod (a licensed S1P1R), and that it is not yet possible to draw any conclusions between the comparative efficacy and safety of these two agents.
Related links: Related editorial